Le Lézard
Classified in: Health
Subjects: LAW, PLW

Argentum Pharmaceuticals Succeeds in Starting Patent Cancellation Trial Against Alcon's TRAVATAN Z®


NEW YORK, Sept. 29, 2017 /PRNewswire/ -- The U.S. Patent & Trademark Office (PTO) granted a petition for inter partes review (IPR) filed by Argentum Pharmaceuticals LLC and its manufacturing partner KVK Tech, against all claims of the last-expiring patent listed as covering Alcon's TRAVATAN Z® (0.004% travoprost solution) drug in the Food & Drug Administration's Orange Book.  Argentum and KVK challenged claims 1-28 of Alcon's U.S. Patent No. 8,268,299, and on September 22, 2017 the PTO concluded there is a "reasonable likelihood that [Argentum] would prevail at trial".  The decision marks the beginning of an IPR trial that will be conducted by three specialist patent judges within the PTO's Patent Trial & Appeal Board (PTAB).  A final decision on patentability in the IPR is due within 1 year.  The successful institution of this petition marks the first time the PTAB has instituted an IPR against this patent.

Argentum Pharmaceuticals. Balancing the rights of pharmaceutical innovators and consumers. (PRNewsFoto/Argentum Pharmaceuticals)

About Argentum Pharmaceuticals

Argentum is a generic drug company with core competencies in intellectual property and pharmaceutical operations. By working with branded and generic pharmaceutical companies and healthcare payors, Argentum intends to reduce the overall cost of prescription drugs by challenging patents that are not innovative and which artificially support high drug prices.  www.argentumpharmaceuticals.com

About KVK Tech

KVK is a recognized leader in the development and manufacture of high-quality, FDA-approved medicines, and possesses operational expertise in pharmaceutical manufacturing, packaging, sales, distribution, research & development, and customer service. KVK's expertise runs the gamut and includes solid oral, powder, liquid, and proprietary dosage technologies.  KVK is in the process of expanding its capabilities into aseptic products as well with a 225,000 sq./ft. sterile injectable facility being qualified this year.  KVK takes pride in its ability to advance medical care and offer low-cost, high-quality alternatives in response to today's healthcare challenges.  KVK is one of the few manufacturers of generic pharmaceuticals which does all its manufacturing, packaging, and distribution in the United States. www.kvktech.com

MADE IN AMERICA. All KVK Tech products are made in the USA in strictest accordance with FDA, DEA, and DEP guidelines.

SOURCE Argentum Pharmaceuticals


These press releases may also interest you

at 00:39
World Malaria Day is marked each year on April 25. World Health Organization (WHO) gave as the theme for World Malaria Day 2024 Accelerating the fight against malaria for a more equitable world. WHO stated that malaria not only continues to directly...

25 avr 2024
The report titled "Anti-Adhesion Products Market by Product Type (Natural Adhesion Barriers, Synthetic Adhesion Barriers), Product Form (Film Formulation, Gel Formulation, Liquid Formulation), Application, End-User - Global Forecast 2024-2030" is now...

25 avr 2024
Product: Meat and vegetable products Issue: Food - Microbial Contamination - Listeria Distribution:British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

25 avr 2024
The report titled "Contract Research Organization Services Market by Type (Clinical Research Services, Consulting Services, Data Management Services), Trial Phase (Phase I, Phase II, Phase III), Therapeutic Area, Molecule Type, End-User - Global...

25 avr 2024
Greenbrook TMS Inc. ("Greenbrook" or the "Company") today announced its fiscal year ended December 31, 2023 ("Fiscal 2023") operational and financial results. All values in this news release are in United States dollars, unless otherwise stated....

25 avr 2024
AIDS Healthcare Foundation applauds the government of Colombia for issuing a compulsory license on HIV drug dolutegravir, which will allow the country to access affordable generic versions of the treatment as an alternative to the costly branded...



News published on and distributed by: